Open AccessA Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer
Author(s) -
Ryu MinHee,
Ryoo BaekYeol,
Kim Tae Won,
Kim Sung Bae,
Lim HyeongSeok,
Bae KyunSeop,
Park Sook Ryun,
Jo YeongWoo,
Cho Hyun Ju,
Kang YoonKoo
Publication year - 2017
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2016-0273
Subject(s) - medicine , neutropenia , paclitaxel , regimen , cancer , febrile neutropenia , adverse effect , pharmacokinetics , chemotherapy , phases of clinical research , gastroenterology , oncology
Ideally, patients should have access to an oral formulation of paclitaxel, as well as an intravenous formulation, to allow development of regimens exploring alternate schedules and to avoid reactions to Cremophor EL (BASF Corp., Ludwigshafen, Germany, https://www.basf.com).DHP107 is a novel oral paclitaxel formulation that is a tolerable and feasible regimen for patients with gastric cancer, with data suggesting efficacy similar to that of intravenous paclitaxel.